Tau pathology is emerging as a mechanistic bridge between epilepsy and dementia
Adult-onset epilepsy most often begins after age 55, placing a growing number of older patients at the intersection of seizures, cognitive decline, and neurodegeneration. The review frames tau pathology as one of the most plausible biological links connecting those outcomes. The central argument is not that tau explains every case of epilepsy, but that tau-related changes may help account for why some patients develop persistent hyperexcitability, worsening memory, and progressive brain dysfunction over time.
In practical terms, the question reaches beyond seizure control. If abnormal tau processing contributes to epileptogenesis and cognitive decline, then epilepsy care in older adults may need to move closer to a neurodegenerative disease model rather than remain focused only on symptom suppression.
How tau biology could amplify hyperexcitability
Tau is normally involved in microtubule stability and neuronal structure, but pathological changes alter its biochemical state and physical behavior. Abnormal phosphorylation can promote misfolding and aggregation, and those structural shifts may interfere with neuronal function in ways that favor network instability. The review traces how those molecular changes are relevant not only to dementia syndromes but also to seizure generation and seizure persistence.
Experimental epilepsy models provide much of the mechanistic support. Across animal work, tau abnormalities have been linked with seizure occurrence and with cognitive impairment, suggesting that the protein may be more than an incidental marker of injury. In human epileptic syndromes, the same conceptual pattern appears: tau-related neurodegenerative processes may contribute to chronic symptoms that extend well past the ictal event itself.
A single protein can sit at the center of two clinical syndromes when it disrupts both circuit stability and neuronal resilience.
Seizures across tauopathies strengthen the bidirectional model
The review examines seizure prevalence in established primary and secondary tauopathies to better define the hyperexcitability phenotype associated with tau burden. That approach matters because it reverses the usual direction of inquiry. Instead of asking only whether epilepsy causes brain injury, it asks whether tau-driven disease states themselves create a seizure-prone brain.
This bidirectional framework fits the broader clinical observation that epilepsy and dementia often coexist and may influence each other over time. Seizures can worsen cognition, and progressive neurodegeneration can lower the threshold for seizures. Tau pathology offers a biologically credible mechanism for both directions of effect, especially in older patients in whom neurodegenerative change may already be underway when seizures first appear.
Biomarkers, imaging, and cognition may need to be measured together
A major theme in the review is measurement. Investigators discuss neurophysiology, metabolic imaging, and novel fluid biomarkers as non-invasive ways to detect underlying neurodegeneration in epilepsy. These tools could help clinicians follow the biological course of disease rather than relying solely on seizure counts, which often miss ongoing cognitive or structural injury.
The article also raises the possibility of combining such measures with remote cognitive assessment and other physiological monitoring to improve longitudinal tracking. That approach is attractive because cognition in epilepsy is not static. Memory complaints, executive dysfunction, and slower processing may evolve alongside subclinical pathology, even when overt seizure frequency appears unchanged.
Fluid biomarkers and imaging could eventually identify which patients are showing a tau-linked neurodegenerative trajectory, and which are not. For a disorder as heterogeneous as epilepsy, that distinction would alter both prognosis and trial design.
Sodium selenate places tau biology into a therapeutic frame
The review gives special attention to clinical efforts that have targeted pathological tau accumulation in neurodegenerative disease, and it also discusses an ongoing epilepsy study using sodium selenate. The compound acts as an enhancer of the protein phosphatase enzyme PP2A, a pathway that may reduce pathological tau burden by promoting tau dephosphorylation.
This is an important translational step because it moves the tau hypothesis from theory toward intervention. The therapeutic logic is straightforward: if abnormal tau contributes to seizure susceptibility and cognitive decline, then reducing that pathological signal could potentially influence both domains. The review characterizes these efforts as part of a disease-modifying era, one in which treatment aims extend beyond seizure suppression to include cognition and underlying biology.
Why the cognitive dimension cannot be separated from seizure care
In older adults, epilepsy is rarely a purely electrical disorder. Memory loss, slowed thinking, and reduced functional reserve can shape outcomes as much as the seizures themselves. The review repeatedly returns to that overlap, arguing that the relationship between tau pathology and cognitive impairment may hold clues to causality rather than simple coexistence.
That distinction has bedside implications. If tau-mediated injury is contributing to both seizures and decline in cognition, then patients may need earlier neuropsychological surveillance, more deliberate imaging and biomarker workup, and closer attention to the possibility that antiseizure therapy alone will not address the full disease burden. A patient whose seizures are controlled can still be progressing biologically.
Brain tissue and peripheral samples remain a key gap
Despite the conceptual progress, the review makes clear that the field still lacks deeper characterization of tau pathology at biochemical and structural levels in both brain tissue and peripheral samples from people with epilepsy. Without that information, the field cannot yet map how tau changes begin, how they evolve, or which patients are most likely to develop a dementia-associated trajectory.
That gap is especially important because epilepsy is not one disease. The review spans primary and secondary tauopathies, animal models, and human syndromes precisely because no single clinical phenotype captures the full biological range. More detailed tissue work could help separate tau as a marker of injury from tau as an active driver of pathogenesis.
The remaining challenge is not whether tau matters in the abstract. The next step is determining which patients carry measurable tau-related pathology, when those changes emerge, and whether intervention can alter both seizures and cognitive decline before irreversible damage takes hold.